Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea.
10.3350/kjhep.2010.16.4.362
- Author:
Sang Ho LEE
1
;
Hyoung Su KIM
;
Kwon Oh PARK
;
Jong Won PARK
;
Seung Yeon CHUN
;
Seung Jin LIM
;
Hyun Jung CHO
;
Sung Jun KIM
;
Hye Won PARK
;
Han Kook MOON
;
Woon Geon SHIN
;
Kyung Ho KIM
;
Myoung Kuk JANG
;
Jin Heon LEE
;
Hak Yang KIM
Author Information
1. Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea. hskim@hallym.or.kr
- Publication Type:Original Article
- Keywords:
Hepatitis A;
Seroprevalence;
Chronic hepatitis B;
Korea
- MeSH:
Adolescent;
Adult;
Age Factors;
Aged;
Female;
Hepatitis A/complications/*epidemiology/prevention & control;
Hepatitis A Antibodies/*blood;
Hepatitis A virus/immunology;
Hepatitis B Surface Antigens/blood;
Hepatitis B, Chronic/*complications;
Humans;
Immunoglobulin G/*blood;
Male;
Middle Aged;
Republic of Korea;
Seroepidemiologic Studies;
Sex Factors;
Vaccination
- From:The Korean Journal of Hepatology
2010;16(4):362-368
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Few studies have investigated hepatitis A virus (HAV) seroepidemiology in Koreans with chronic liver disease (CLD). This study compared the prevalence of IgG anti-HAV between the general healthy population and patients with hepatitis B virus-related CLD (HBV-CLD), with the aim of identifying predictors of HAV prior exposure. METHODS: In total, 1,319 patients were recruited between June 2008 and April 2010. All patients were tested for IgG anti-HAV, hepatitis B surface antigen (HBsAg), and antibodies to hepatitis C virus. The patients were divided into the general healthy population group and the HBV-CLD group based on the presence of HBsAg. The seroprevalence of IgG anti-HAV was compared between these two groups. RESULTS: The age-standardized seroprevalence rates of IgG anti-HAV in the general healthy population and patients with HBV-CLD were 52.5% and 49.1%, respectively. The age-stratified IgG anti-HAV seroprevalence rates for ages < or =19, 20-29, 30-39, 40-49, 50-59, and > or =60 years were 14.3%, 11.2%, 45.5%, 90.5%, 97.6% and 98.3%, respectively, in the general healthy population, and 0%, 9.8%, 46.3%, 91.1%, 97.7%, and 100% in the HBV-CLD group. In multivariate analysis, age (<30 vs. 30-59 years: OR=19.339, 95% CI=12.504-29.911, P<0.001; <30 vs. > or =60 years: OR=1060.5, 95% CI=142.233-7907.964, P<0.001) and advanced status of HBV-CLD (OR=19.180, 95% CI=4.550-80.856, P<0.001) were independent predictors of HAV prior exposure. CONCLUSIONS: The seroprevalence of IgG anti-HAV did not differ significantly between the general-healthy-population and HBV-CLD groups. An HAV vaccination strategy might be warranted in people younger than 35 years, especially in patients with HBV-CLD.
